{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:13:18Z","timestamp":1749701598944,"version":"3.41.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HIV Prevention Trials Network","award":["U01-AI068619"],"award-info":[{"award-number":["U01-AI068619"]}]},{"DOI":"10.13039\/100011072","name":"Center for AIDS Research, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30-AI50410"],"award-info":[{"award-number":["P30-AI50410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2020143"],"award-info":[{"award-number":["2020143"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>We explored perceptions of long-acting injectable (LAI) patient prioritization and decision-making among people who inject drugs (PWID) with HIV, HIV clinic staff, and policymakers in Vietnam.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>From February to November 2021, we conducted 38 interviews with 19 PWID, 14 HIV clinic staff, and 5 policymakers in Hanoi, Vietnam. Interviews were coded and analyzed using thematic analysis to assess themes across participants.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>PWID highlighted the importance of medical providers in treatment decisions, while clinic staff stressed adequate counseling and patient choice. Non-patient participants viewed adherence to Ministry of Health guidelines as essential, and many clinic staff saw PWID as ideal for LAI due to suboptimal adherence. Policymakers, however, preferred prioritizing LAI based on viral suppression and adherence rather than risk behaviors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study reveals conflicting stakeholder views on LAI prioritization, suggesting a need for a more nuanced implementation approach to balance efficiency and fairness in low-resource settings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325195","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:32:13Z","timestamp":1749663133000},"page":"e0325195","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prioritizing long-acting injectable antiretroviral therapy among key populations: Perceptions of persons living with HIV who inject drugs, ART clinic staff, and policymakers in Vietnam"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-5654","authenticated-orcid":true,"given":"Minh X.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian F.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adams L.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna E.","family":"Huffstetler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang N.T.","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha V.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le M.","family":"Giang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerada","family":"Sripaipan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Rutstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"pone.0325195.ref001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijid.2020.09.011","article-title":"Ending the epidemic of HIV\/AIDS by 2030: will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries?","volume":"100","author":"Y Assefa","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0325195.ref002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12981-023-00557-5","article-title":"Assessment of satisfaction with antiretroviral drugs and the need for long-acting injectable medicines among people living with HIV in Japan and its associated factors: a prospective multicenter cross-sectional observational study","volume":"20","author":"M Ishihara","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"1","key":"pone.0325195.ref003","doi-asserted-by":"crossref","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"SH Bares","year":"2022","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"5","key":"pone.0325195.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"JB Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"pone.0325195.ref005","unstructured":"FDA Approves First Extended-Release. Injectable drug regimen for adults living with HIV [press release]. 2021 January 21."},{"key":"pone.0325195.ref006","author":"ViiV Healthcare","year":"2020","journal-title":"ViiV Healthcare announces the marketing authorisation of the first complete long-acting injectable HIV treatment in Europe"},{"key":"pone.0325195.ref007","unstructured":"World Health Organization. Who announces the development of new guidance on offering long acting injectable cabotegravir as HIV prevention for people at substantial risk for hiv infection. 2022. Available from: https:\/\/www.who.int\/news\/item\/17-02-2022-who-announces-guidelines-development-group-cabotegravir."},{"issue":"4","key":"pone.0325195.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"C Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"10267","key":"pone.0325195.ref009","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"ET Overton","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"pone.0325195.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262926","article-title":"Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County","volume":"17","author":"O Jolayemi","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0325195.ref011","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s43058-023-00506-3","article-title":"Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives","volume":"4","author":"KA Koester","year":"2023","journal-title":"Implement Sci Commun"},{"key":"pone.0325195.ref012","first-page":"100603","article-title":"Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: a qualitative study","volume":"31","author":"SE Rutstein","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"pone.0325195.ref013","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac752","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of HIV in low- and middle-income countries (LMICs)","volume":"75","author":"C Kityo","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0325195.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00025-5","article-title":"The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis","volume":"9","author":"AN Phillips","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"4","key":"pone.0325195.ref015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11908-015-0466-9","article-title":"What we know and what we do not know about factors associated with and interventions to promote antiretroviral adherence","volume":"17","author":"S Mannheimer","year":"2015","journal-title":"Curr Infect Dis Rep"},{"issue":"9","key":"pone.0325195.ref016","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0956462413516301","article-title":"Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam","volume":"25","author":"MR Jordan","year":"2014","journal-title":"Int J STD AIDS"},{"issue":"1","key":"pone.0325195.ref017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13011-020-00271-9","article-title":"Treatment adherence amongst drug users attending public and private methadone maintenance clinics in a northern province of Vietnam","volume":"15","author":"TA Le","year":"2020","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"pone.0325195.ref018","unstructured":"Vietnam Administrative for AIDS Control. An annual update on the HIV epidemic in Viet Nam. 2014."},{"key":"pone.0325195.ref019","article-title":"Prevalence and shared risk factors of HIV in three key populations in Vietnam: a systematic review and meta-analysis","volume":"151","author":"P Lee","year":"2023","journal-title":"Epidemiol Infect"},{"key":"pone.0325195.ref020","first-page":"1","article-title":"Implementing long-acting injectable antiretroviral treatments in senegal: issues, challenges and conditions for introducing them qualitative study with healthcare providers and patients","author":"S Carillon","journal-title":"AIDS Care"},{"issue":"6","key":"pone.0325195.ref021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1521\/aeap.2023.35.6.467","article-title":"What is the benefit?: Perceptions and preferences for long-acting injectable antiretroviral therapy among people living with HIV","volume":"35","author":"H RodriguezGonzalez","year":"2023","journal-title":"AIDS Educ Prev"},{"issue":"3","key":"pone.0325195.ref022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/apc.2018.0198","article-title":"Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV","volume":"33","author":"JM Simoni","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0325195.ref023","doi-asserted-by":"crossref","first-page":"23259582211000517","DOI":"10.1177\/23259582211000517","article-title":"Lighten this burden of ours: acceptability and preferences regarding injectable antiretroviral treatment among adults and youth living with HIV in coastal Kenya","volume":"20","author":"JM Simoni","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"pone.0325195.ref024","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/COH.0000000000000158","article-title":"Implementation challenges for long-acting antivirals as treatment","volume":"10","author":"D Havlir","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"pone.0325195.ref025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","article-title":"Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials","volume":"21","author":"A Mantsios","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"pone.0325195.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055750","article-title":"Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation","volume":"8","author":"DB Nguyen","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"pone.0325195.ref027","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s40121-023-00840-y","article-title":"Cabotegravir and rilpivirine long-acting antiretroviral therapy administered every 2 months is cost-effective for the treatment of HIV-1 in Spain","volume":"12","author":"S Moreno","year":"2023","journal-title":"Infectious Diseases Therapy"},{"issue":"2","key":"pone.0325195.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245955","article-title":"Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study","volume":"16","author":"B Parker","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"pone.0325195.ref029","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/cid\/ciu1159","article-title":"The clinical role and cost-effectiveness of long-acting antiretroviral therapy","volume":"60","author":"EL Ross","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0325195.ref030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10461-014-0928-3","article-title":"Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review","volume":"19","author":"J Feelemyer","year":"2015","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0325195.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"D Kerrigan","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"pone.0325195.ref032","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s10461-020-02973-4","article-title":"Shared decision making between patients and healthcare providers and its association with favorable health outcomes among people living with HIV","volume":"25","author":"C Okoli","year":"2021","journal-title":"AIDS Behav"},{"issue":"2","key":"pone.0325195.ref033","doi-asserted-by":"crossref","first-page":"23814683211061398","DOI":"10.1177\/23814683211061398","article-title":"Patient-reported roles in decision-making among asian patients with advanced cancer: a multicountry study","volume":"6","author":"S Ozdemir","year":"2021","journal-title":"MDM Policy Pract"},{"key":"pone.0325195.ref034","first-page":"54","article-title":"Finding what works: identification of implementation strategies for the integration of methadone maintenance therapy and HIV services in Vietnam","volume":"11","author":"VF Go","year":"2016","journal-title":"Implement Sci"},{"issue":"1","key":"pone.0325195.ref035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12910-015-0059-z","article-title":"Paternalism and autonomy: views of patients and providers in a transitional (post-communist) country","volume":"16","author":"L Murgic","year":"2015","journal-title":"BMC Med Ethics"},{"issue":"6","key":"pone.0325195.ref036","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1111\/hex.12313","article-title":"Shared decision making and the use of a patient decision aid in advanced serious illness: provider and patient perspectives","volume":"18","author":"J Jones","year":"2015","journal-title":"Health Expect"},{"key":"pone.0325195.ref037","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v3i0.4625","article-title":"The evolution of HIV policy in Vietnam: from punitive control measures to a more rights-based approach","volume":"3","author":"P Nguyen Ha","year":"2010","journal-title":"Glob Health Action"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:32:21Z","timestamp":1749663141000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325195"}},"subtitle":[],"editor":[{"given":"Ali","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325195","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}